# Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Study · id `cardio:ct-nct01674647` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01674647](<https://clinicaltrials.gov/study/NCT01674647>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01674647

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1504 participants.

## Technical summary

Registry record NCT01674647. Randomized; no masking; primary purpose prevention. Start 2012-10 (registry gives no type); primary completion 2014-01 (actual). Results posted on 2015-02-03.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 1504 participants (enrolled count; ClinicalTrials.gov record NCT01674647, source copy `cardio:ctgov-nct01674647-2015-04-30`, retrieved 2026-10-26)
- Start date: 2012-10 (registry gives no type) (ClinicalTrials.gov record NCT01674647, source copy `cardio:ctgov-nct01674647-2015-04-30`, retrieved 2026-10-26)
- Primary completion: 2014-01 (actual) (ClinicalTrials.gov record NCT01674647, source copy `cardio:ctgov-nct01674647-2015-04-30`, retrieved 2026-10-26)
- Completion: 2014-01 (actual) (ClinicalTrials.gov record NCT01674647, source copy `cardio:ctgov-nct01674647-2015-04-30`, retrieved 2026-10-26)
- Results first posted: 2015-02-03 (ClinicalTrials.gov record NCT01674647, source copy `cardio:ctgov-nct01674647-2015-04-30`, retrieved 2026-10-26)
- Countries: United States; Belgium; Brazil; Canada; China; Denmark; Finland; France; Germany; Greece; Italy; Netherlands; Portugal; Singapore; South Africa; Spain; United Kingdom (ClinicalTrials.gov record NCT01674647, source copy `cardio:ctgov-nct01674647-2015-04-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01674647-2015-04-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
- Acronym: X-VERT
- Condition: Atrial Fibrillation
- Intervention (Drug): Rivaroxaban (Xarelto, BAY59-7939)
- Intervention (Drug): Vitamin K antagonist (VKA)
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY
- Collaborator: Janssen Research & Development, LLC
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)
- Registry lists this organization as a collaborator: Janssen Research & Development, LLC (`cardio:org-janssen-research-development-llc`)

## Provenance

Content hash: 8b2c7d8637e75c2dcf45d6c18a5ff40392a646375dc6e657f5da9bc9807473d2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
